United Therapeutics Corporation UTHR
584.10 USD -3.78 (-0.64%)
Regular-session close
584.10 0.00 0.00%
After hours · Nov 17, 5:45 PM ET
575.41 Day range 587.78
455.63 52-week range 614.23
- YTD
- +19.88%
- 1 year
- +23.77%
News
seekingalpha.com United Therapeutics Corporation (UTHR) Presents at Jefferies Global Healthcare Conference 2026 Transcript United Therapeutics Corporation (UTHR) Presents at Jefferies Global Healthcare Conference 2026 Transcript
marketbeat.com United Therapeutics Prepares for TYVASO Expansion After $833 Million Quarter United Therapeutics NASDAQ: UTHR is preparing for a potential expansion of its TYVASO franchise into idiopathic pulmonary fibrosis, while its executives pointed to strong third-quarter sales and a…
zacks.com SGIOY or UTHR: Which Is the Better Value Stock Right Now? Investors looking for stocks in the Medical - Drugs sector might want to consider either Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) or United Therapeutics (UTHR).
seekingalpha.com United Therapeutics Corporation (UTHR) Presents at UBS Global Biopharma Conference 2026 Transcript United Therapeutics Corporation (UTHR) Presents at UBS Global Biopharma Conference 2026 Transcript
defenseworld.net 5,137 United Therapeutics Corporation $UTHR Shares Purchased by Fisher Asset Management LLC Fisher Asset Management LLC grew its position in United Therapeutics Corporation (NASDAQ: UTHR) by 15.2% during the third quarter, according to the company in its most recent disclosure with the…
benzinga.com Here's How Much $100 Invested In United Therapeutics 15 Years Ago Would Be Worth Today United Therapeutics (NASDAQ:UTHR) has outperformed the market over the past 15 years by 6.56% on an annualized basis producing an average annual return of 19.5%. Currently, United Therapeutics has a…
gurufocus.com United Therapeutics Corporation Announces Participation at Upcoming Investor Conferences United Therapeutics Corporation (Nasdaq: UTHR) announced today that James Edgemond, Chief Financial Officer and Treasurer, will provide an overview and update d
247wallst.com Buy, Sell, or Hold? Monday’s Top Upgrades and Downgrades: Advanced Micro Devices, Airbnb, DraftKings, L3 Harris Technologies, Molson-Coors, Nvidia, Take-Two Interactive, Uber Technologies, and More Nvidia just lost a vote of confidence while AMD earned a $600 target, and Wall Street's chip debate is splitting wide open. Add a Fed rate hike looming and a flurry of fresh Citigroup calls, and…
businesswire.com United Therapeutics Corporation Announces Participation at Upcoming Investor Conferences SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that James Edgemond, Chief Financial Officer and Treasurer, will…benzinga.com HC Wainwright & Co. Assumes United Therapeutics at Buy, Announces Price Target of $660 HC Wainwright & Co. analyst Matthew Caufield assumes United Therapeutics (NASDAQ:UTHR) with a Buy rating and announces Price Target of $660.
benzinga.com TD Cowen Maintains Buy on United Therapeutics, Raises Price Target to $700 TD Cowen analyst Joseph Thome maintains United Therapeutics (NASDAQ:UTHR) with a Buy and raises the price target from $675 to $700.
benzinga.com RBC Capital Maintains Outperform on United Therapeutics, Raises Price Target to $725 RBC Capital analyst Lisa Walter maintains United Therapeutics (NASDAQ:UTHR) with a Outperform and raises the price target from $697 to $725.
benzinga.com Wells Fargo Maintains Overweight on United Therapeutics, Raises Price Target to $703 Wells Fargo analyst Benjamin Burnett maintains United Therapeutics (NASDAQ:UTHR) with a Overweight and raises the price target from $700 to $703.
marketbeat.com What United Therapeutics (UTHR) Said on Its Q3 Earnings Call United Therapeutics NASDAQ: UTHR reported record third-quarter 2026 revenue of $833 million, driven in part by record Tyvaso sales of $504 million, while pushing back a planned regulatory submission…
seekingalpha.com United Therapeutics Corporation (UTHR) Q3 2026 Earnings Call Transcript United Therapeutics Corporation (UTHR) Q3 2026 Earnings Call Transcriptbenzinga.com BTIG Maintains Buy on United Therapeutics, Raises Price Target to $768 BTIG analyst Julian Harrison maintains United Therapeutics (NASDAQ:UTHR) with a Buy and raises the price target from $728 to $768.
zacks.com United Therapeutics (UTHR) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates Although the revenue and EPS for United Therapeutics (UTHR) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare…
zacks.com United Therapeutics (UTHR) Q3 Earnings Miss Estimates United Therapeutics (UTHR) came out with quarterly earnings of $5.71 per share, missing the Zacks Consensus Estimate of $5.85 per share. This compares to earnings of $7.16 per share a year ago.benzinga.com United Therapeutics Amends Agreement With Arena Pharmaceuticals, Pfizer Subsidiary, Eliminating All Royalty Obligations Under Its Exclusive License Agreement Related to Ralinepag for an Upfront Payment of $525M This transaction demonstrates our confidence in the revenue opportunity for oral ralinepag, which has a pending new drug application under review by the FDA for pulmonary arterial hypertension, as…
businesswire.com United Therapeutics Announces Buydown of Ralinepag Royalty SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that it has entered into an amendment…
businesswire.com United Therapeutics Corporation Reports Third Quarter 2026 Financial Results SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter…
benzinga.com ARM, McDonald's On Deck Wednesday As AI Demand, Consumer Spending Face Test ARM Holdings headlines Wednesday’s reports, with investors looking for evidence that AI-related demand can support the chip designer after a sharp stock pullback. McDonald’s, Novo Nordisk, Uber…
benzinga.com SpaceX Launch Customer Varda Says a Single Flight Could Help Make Medicine for Millions Varda says one SpaceX flight could produce drug crystals capable of supporting medicine for millions of patients.
zacks.com SGIOY vs. UTHR: Which Stock Is the Better Value Option? Investors interested in stocks from the Medical - Drugs sector have probably already heard of Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) and United Therapeutics (UTHR).benzinga.com JP Morgan Maintains Overweight on United Therapeutics, Lowers Price Target to $695 JP Morgan analyst Jessica Fye maintains United Therapeutics (NASDAQ:UTHR) with a Overweight and lowers the price target from $710 to $695.
zacks.com Analysts Estimate United Therapeutics (UTHR) to Report a Decline in Earnings: What to Look Out for United Therapeutics (UTHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
benzinga.com $100 Invested In United Therapeutics 15 Years Ago Would Be Worth This Much Today United Therapeutics (NASDAQ:UTHR) has outperformed the market over the past 15 years by 6.41% on an annualized basis producing an average annual return of 19.23%. Currently, United Therapeutics has a…
businesswire.com United Therapeutics Announces FDA Clearance to Proceed with Clinical Trial for Treprostinil-Iloprost SMI in Pulmonary Arterial Hypertension SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the U.S. Food and Drug…
defenseworld.net United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of Company Stock United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction on Friday, October 23rd. The shares were sold at an average…benzinga.com RBC Capital Maintains Outperform on United Therapeutics, Lowers Price Target to $697 RBC Capital analyst Lisa Walter maintains United Therapeutics (NASDAQ:UTHR) with a Outperform and lowers the price target from $708 to $697.
businesswire.com United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization SILVER SPRING, M.D. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the company's Board of…benzinga.com United Therapeutics Opens Third Designated Pathogen-Free Facility, The Dr. Bartley P. Griffith And Dr. Robert A. Montgomery Xenograft Production Facility, In Houston, Texas Named for Dr. Bartley P. Griffith and Dr. Robert A. Montgomery, pioneers in xenotransplantation, the biosecure facility is purpose-built to manufacture United Therapeutics’ xenokidneys and xenohearts…
benzinga.com Here’s How Much You Would Have Made Owning United Therapeutics Stock In The Last 5 Years United Therapeutics (NASDAQ:UTHR) has outperformed the market over the past 5 years by 11.98% on an annualized basis producing an average annual return of 23.16%. Currently, United Therapeutics has a…benzinga.com Leerink Partners Maintains Outperform on United Therapeutics, Raises Price Target to $725 Leerink Partners analyst Roanna Ruiz maintains United Therapeutics (NASDAQ:UTHR) with a Outperform and raises the price target from $685 to $725.
benzinga.com The FDA Clears United Therapeutics' Investigational New Drug Application To Proceed With SUMMIT Trial Of Treprostinil Soft Mist Inhaler In Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance under the company’s…
